Analytical Data
-
Gene name
FAM217A
- Application
-
Alternative Names
C6orf146
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8IXS0
-
Expression Region
1-508aa
-
Molecular Weight
61.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FAM217A, a member of the FAM217 family of proteins, has garnered attention in recent years due to its potential roles in cellular processes and implications for various diseases. This protein is involved in crucial biological functions, including cell proliferation, differentiation, and apoptosis, making it a subject of interest in cancer research. Recent studies have suggested that FAM217A may act as an important regulator of oncogenic pathways, influencing tumor progression and metastasis. Additionally, gene expression analyses have indicated that FAM217A is differentially expressed in several cancer types, which raises the possibility of its use as a biomarker for diagnosis or prognosis. The recombinant expression of FAM217A facilitates in-depth functional analysis through the production of large quantities of the protein, enabling researchers to investigate its biochemical properties, interaction with other proteins, and influence on cellular signaling pathways. Understanding the precise mechanisms by which FAM217A contributes to disease may provide new avenues for therapeutic interventions. Furthermore, the study of FAM217A in the context of autoimmune diseases and other cellular dysfunctions is emerging, suggesting its broader relevance in human health. Overall, ongoing research into FAM217A and its recombinant protein applications promises to shed light on its biological significance and potential therapeutic roles across a range of pathological conditions.
